SEC Form 4 · accession 0001179110-15-012462
Esperion Therapeutics, Inc. · ESPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mary McGowan
Officer — Chief Medical Officer
Period of report
Aug 19, 2015
Accepted (ET)
Aug 21, 2015 · 4:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001434868
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 19, 2015 | A | 15,000 | $0.00 | A | 15,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $57.54 | Aug 19, 2015 | A | 210,000 | A | — | Aug 19, 2025 | Common Stock | 210,000 | 210,000 | D |
Explanation of responses
- F1These shares were acquired pursuant to a restricted stock unit award under the 2013 Amended and Restated Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Esperion Therapeutics, Inc. common stock. 25% of the restricted stock units vest on June 15, 2016 and the remainder shall vest in equal quarterly installments over a three (3) year period thereafter, subject to continued service.
- F225% of option vests on June 15, 2016 and the remainder shall vest in equal quarterly installments over a three (3) year period thereafter.